Chronic Kidney Disease in Metabolic Disease: Regulation of SGLT2 and Transcriptomic–Epigenetic Effects of Its Pharmacological Inhibition
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27020589 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Chiara Salvà und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Medical University of Innsbruck, 6020 Innsbruck, Austria. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2, Sodium-Glucose Transporter 2 Inhibitors, Epigenesis, Genetic, Renal Insufficiency, Chronic. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sodium–glucose cotransporter 2 inhibitors (SGLT2is) have revolutionized the management of type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD), providing cardiorenal and metabolic benefits that extend beyond glycemic control. While their clinical efficacy is well established, the underlying molecular mechanisms remain only partially understood. This review focuses on current knowledge of SGLT2 expression and regulation in health and metabolic diseases, as well as transcriptional and epigenetic consequences of pharmacological SGLT2 inhibition. Human and experimental studies demonstrate that SGLT2 expression is confined to proximal tubular cells and regulated by insulin, the renin–angiotensin–aldosterone system, the sympathetic nervous system, oxidative stress, and transcriptional and epigenetic pathways. SGLT2 expression follows a biphasic pattern in metabolic disorder-associated CKD: upregulation in early phases and reduction in advanced stages. Evidence from animal models and single-cell transcriptomic studies indicates that SGLT2is normalize metabolic and inflammatory gene networks. To our knowledge, a recent single-cell RNA sequencing study provides the only currently available human dataset linking SGLT2i therapy with tubular metabolic rewiring and suppression of the energy-sensitive mechanistic target of rapamycin complex 1. Collectively, these findings support a model in which SGLT2 inhibition mitigates metabolic stress by restoring energy homeostasis across multiple nephron segments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, Medical University of Innsbruck, 6020 Innsbruck, Austria.
- Clinical and Molecular Sciences Department, University Politecnica delle Marche, 60126 Ancona, Italy.
ORCID-Profile: Chiara Salvà, Susanne Kaser, Matteo Landolfo
Zitieren
APA
Salvà, C., Kaser, S., & Landolfo, M. (2026). Chronic Kidney Disease in Metabolic Disease: Regulation of SGLT2 and Transcriptomic–Epigenetic Effects of Its Pharmacological Inhibition. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020589
Vancouver
Salvà C, Kaser S, Landolfo M. Chronic Kidney Disease in Metabolic Disease: Regulation of SGLT2 and Transcriptomic–Epigenetic Effects of Its Pharmacological Inhibition. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020589
BibTeX
@article{Salv2026,
author = {Salvà, Chiara and Kaser, Susanne and Landolfo, Matteo},
title = {Chronic Kidney Disease in Metabolic Disease: Regulation of SGLT2 and Transcriptomic–Epigenetic Effects of Its Pharmacological Inhibition},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27020589}
}
EUVIMED